| Drugmaker 
                                        Admits Claritin Kickback Scheme July 30, 2004 Schering-Plough will pay the federal government 
                                        and 49 states $282 million to settle a 
                                        Medicaid fraud case involving its Claritin 
                                        allergy drug. The company will also plead 
                                        guilty to criminal charges of violating 
                                        the Anti-Kickback Statute and pay the 
                                        federal government a $52 million fine, 
                                        U.S. Attorney Patrick Meehan said.
 Schering-Plough defrauded Medicaid, a 
                                        health insurance program for the poor 
                                        administered by the federal government 
                                        and the states, by failing to report the 
                                        correct "best" or lowest price 
                                        for its Claritin allergy drug, as required 
                                        by law. The company granted secret discounts 
                                        on Claritin to two large HMOs, Pacificare 
                                        and CIGNA, but failed to include the data 
                                        in calculating the drug's "best" 
                                        or lowest price. As a result, the best 
                                        price reported to Medicaid was higher 
                                        than the true best price, resulting in 
                                        smaller rebates to the states and the 
                                        federal government. Schering-Plough gave Pacificare and CIGNA 
                                        price breaks on Claritin after the HMOs 
                                        threatened to drop the allergy medicine 
                                        for a cheaper drug. The company hid the 
                                        discounts by providing them to the HMOs 
                                        in the form of "fees," interest 
                                        free loans, price breaks on other medications 
                                        and side agreements. "Schering-Plough's Claritin con 
                                        has been exposed and stopped: this drug 
                                        company proved allergic to lawful, fair 
                                        business practices – boosting sales 
                                        of its allergy drug Claritin through a 
                                        scheme of concealed discounts," Connecticut 
                                        Attorney General Richard Blumenthal said. 
                                       "The company defrauded Connecticut, 
                                        other state and federal taxpayers of hundreds 
                                        of millions of dollars and now must pay. 
                                        The company resorted to a cynical subterfuge, 
                                        creating a complex scheme to deceive federal 
                                        and state officials. Phony fees, fake 
                                        agreements, false loans, all were intended 
                                        to further fatten the company's profits 
                                        at consumers' ultimate expense. This scheme 
                                        is enough to make anyone gag and choke." The U. S. Department of Justice and the 
                                        National Association of Medicaid Fraud 
                                        Control Units, an anti-Medicaid fraud 
                                        coalition of state officials, also took 
                                        part in the investigation of the scam 
                                        and resulting settlement.    |